Avalo Therapeutics (AVTX) announced the appointment of Kevin Lind to its Board of Directors. He most recently served as President, CEO, and Board Member of Longboard Pharmaceuticals.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data
- 3 Best Stocks to Buy Now, 9/12/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 9/5/2025, According to Top Analysts
- Buy Rating for Avalo Therapeutics Driven by Promising AVTX-009 Development and Market Potential